Cabaletta Bio, Inc. financial data

Symbol
CABA on Nasdaq
Location
Philadelphia, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448% % -61%
Debt-to-equity 29% % 188%
Return On Equity -107% % -114%
Return On Assets -83% % -82%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96,265,204 shares 97%
Common Stock, Shares, Outstanding 96,265,204 shares 97%
Entity Public Float $350,000,000 USD -29%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 1,168,054 shares -72%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $132,012,000 USD 48%
General and Administrative Expense $31,403,000 USD 24%
Operating Income (Loss) $163,415,000 USD -43%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $158,523,000 USD -52%
Earnings Per Share, Basic -2 USD/shares -18%
Earnings Per Share, Diluted -2 USD/shares -18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $60,206,000 USD -65%
Cash, Cash Equivalents, and Short-term Investments $159,931,000 USD -13%
Assets, Current $164,561,000 USD -11%
Property, Plant and Equipment, Net $2,063,000 USD -27%
Operating Lease, Right-of-Use Asset $3,597,000 USD -74%
Other Assets, Noncurrent $3,607,000 USD 45%
Assets $189,759,000 USD -7.2%
Accounts Payable, Current $8,267,000 USD 279%
Employee-related Liabilities, Current $6,764,000 USD 32%
Liabilities, Current $45,735,000 USD 100%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $50,293,000 USD 67%
Accumulated Other Comprehensive Income (Loss), Net of Tax $23,000 USD 2200%
Retained Earnings (Accumulated Deficit) $475,038,000 USD -50%
Stockholders' Equity Attributable to Parent $139,466,000 USD -20%
Liabilities and Equity $189,759,000 USD -7.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $30,802,000 USD -28%
Net Cash Provided by (Used in) Financing Activities $552,000 USD -108%
Net Cash Provided by (Used in) Investing Activities $785,000 USD 3.3%
Common Stock, Shares Authorized 300,000,000 shares 100%
Common Stock, Shares, Issued 96,265,204 shares 97%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $32,132,000 USD -79%
Interest Paid, Excluding Capitalized Interest, Operating Activities $208,000 USD
Deferred Tax Assets, Valuation Allowance $110,723,000 USD 53%
Deferred Tax Assets, Gross $114,661,000 USD 55%
Depreciation $485,000 USD 23%
Payments to Acquire Property, Plant, and Equipment $785,000 USD -3.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $158,501,000 USD -52%
Lessee, Operating Lease, Liability, to be Paid $3,626,000 USD -76%
Property, Plant and Equipment, Gross $8,249,000 USD 30%
Operating Lease, Liability, Current $3,626,000 USD -54%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $200,000 USD -89%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $1,252,000 USD 120%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $3,938,000 USD 172%
Interest Expense $2,197,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%